Scilex Holding (SCLX) Other Non-Current Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Other Non-Current Liabilities of $25.5 million for Q1 2026, up 223.55% year-over-year from $7.9 million in Q1 2025, and up 14578.74% quarter-over-quarter from $174000.0 in Q4 2025.
Scilex Holding (SCLX) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $25.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 223.55% year-over-year to $25.5 million; the TTM figure through Mar 2026 stood at $25.5 million (up 223.55% YoY), while the FY2025 annual figure was $174000.0, down 82.6% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $25.5 million, up from $174000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $110.1 million in Q4 2023, with the low at $155000.0 in Q3 2024.
- The 5-year median for Other Non-Current Liabilities is $1.2 million (2022), against an average of $13.9 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 99.09% in 2024, then soared 36212.83% in 2025.
- Scilex Holding's Other Non-Current Liabilities stood at $1.2 million in 2022, then surged by 8846.06% to $110.1 million in 2023, then plunged by 99.09% to $1.0 million in 2024, then sank by 82.6% to $174000.0 in 2025, then soared by 14578.74% to $25.5 million in 2026.
- Business Quant data shows SCLX's Other Non-Current Liabilities at $25.5 million in Q1 2026, $174000.0 in Q4 2025, and $169000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.54 Mn |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | 67.91 Mn |
| Mar 31, 2025 | 7.89 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 187,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 110.13 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 6.57 Mn |
| Mar 31, 2023 | 6.48 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 35.70 Mn |
| Sep 30, 2021 | 4.86 Mn |
| Jun 30, 2021 | 3.69 Mn |